Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Prolonged-Release Tablets 30 X 18 mg |
|
||
|
Prolonged-Release Tablets 30 X 27 mg |
|
||
|
Prolonged-Release Tablets 30 X 36 mg |
|
||
|
Prolonged-Release Tablets 30 X 54 mg |
|
Related information
Dosage
Please refer to the license holder for further details.
Indications
Indicated for the treatment of attention deficit hyperactivity disorder (ADHD)
Contra-Indications
* Hypersensitivity to methylphenidate or to any of the excipients.
* Tics or Tourette’s syndrome or a family history of Tourette’s
Syndrome
* Use of antidepressant from the monoamine oxidase inhibitor (MAOI) group in the last 14 days before
* Children under the age of 6
Special Precautions
Please refer to the license holder for further details.
Side Effects
Please refer to the license holder for further details.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details.
Overdose
Please refer to the license holder for further details.
Important notes
Please refer to the license holder for further details.
